Mitsubishi UFJ Trust & Banking Corp Has $16.13 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Mitsubishi UFJ Trust & Banking Corp trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 7.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,703 shares of the biotechnology company’s stock after selling 3,723 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned 0.10% of United Therapeutics worth $16,126,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after acquiring an additional 30 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 30 shares during the period. Great Lakes Advisors LLC lifted its position in United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after acquiring an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after acquiring an additional 39 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

Insider Buying and Selling

In other news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,755 shares of company stock valued at $29,792,021. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Down 0.3 %

United Therapeutics stock opened at $306.97 on Friday. The stock has a market cap of $13.79 billion, a P/E ratio of 13.48, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The company’s 50-day moving average price is $340.06 and its two-hundred day moving average price is $355.69.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the firm posted $4.36 EPS. Equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.